Foghorn Therapeutics Inc
FHTX
Company Profile
Business description
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Contact
500 Technology Square
Suite 700
CambridgeMA02139
USAT: +1 617 586-3100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
112
Stocks News & Analysis
stocks
After earnings, is Uber stock a buy, a sell, or fairly valued?
With results exceeding management’s forecast for Q3, here’s what we think of Uber stock.
stocks
The largest share trading on the ASX remains materially overvalued
Profit barely budges on the most expensive bank in the world.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.40 | 53.80 | -0.59% |
| CAC 40 | 8,156.23 | 100.72 | 1.25% |
| DAX 40 | 24,088.06 | 128.07 | 0.53% |
| Dow JONES (US) | 47,936.46 | 567.83 | 1.20% |
| FTSE 100 | 9,899.60 | 112.45 | 1.15% |
| HKSE | 26,696.41 | 47.35 | 0.18% |
| NASDAQ | 23,492.33 | 34.84 | -0.15% |
| Nikkei 225 | 50,842.93 | 68.83 | -0.14% |
| NZX 50 Index | 13,604.55 | 12.93 | -0.09% |
| S&P 500 | 6,852.77 | 20.34 | 0.30% |
| S&P/ASX 200 | 8,818.80 | 56.80 | -0.64% |
| SSE Composite Index | 4,002.76 | 15.84 | -0.39% |